CN101209111A - Edible composition capable of increasing bone density - Google Patents
Edible composition capable of increasing bone density Download PDFInfo
- Publication number
- CN101209111A CN101209111A CNA2006101483832A CN200610148383A CN101209111A CN 101209111 A CN101209111 A CN 101209111A CN A2006101483832 A CNA2006101483832 A CN A2006101483832A CN 200610148383 A CN200610148383 A CN 200610148383A CN 101209111 A CN101209111 A CN 101209111A
- Authority
- CN
- China
- Prior art keywords
- component
- dosage
- group
- bone
- bone density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to an edible health care product, in particular to an edible composition to increase bone density. The composition includes the following components and the dose ranges: (1) 25mg/kg to 600mg/kg of epimedium herb extract (calculating as the Icariin); (2) 25mg/kg to 600mg/kg of collagen protein. The invention has good effect of increasing the bone density.
Description
Technical field
The present invention relates to a kind of edible health care product, particularly a kind of edible composition that increases bone density.
Background technology
Chinese invention patent prospectus (publication number: CN1416728A) disclose a kind of increase bone density and anti-aging health food, it is with soybean, barrenwort, the Radix Astragali, Radix Angelicae Sinensis and mulberry fruit are active ingredient, join again with the auxiliary material calcium gluconae, sodium carboxymethyl starch and microcrystalline cellulose are formed.The preparation method of this health food will pass through supercritical CO
2The Angelica oil that extraction process makes, the soybean isoflavone extract that soybean makes by alcohol extract, with by barrenwort, the Radix Astragali, mulberry fruit and carry oil after the spray powder that makes after extracting by water and handling of angelica powder fully mix, add calcium gluconae again, sodium carboxymethyl starch and microcrystalline cellulose, make particle, compressing tablet again, dressing, tablet gets product.Zoopery proves that this product has the bone density of increasing and function in delaying senility.Modern pharmacology and clinical research show that this product has the health care that increases bone density and delay senility, and suit to take for a long time as health food.
But the composition in the above-mentioned composition is not all to play effect to increasing bone density, and does not disclose only dosage.
Summary of the invention
The purpose of this invention is to provide a kind of edible composition that increases bone density, disclosed component and dosage can solve existing technical problem in the above-mentioned prior art.
The solution that realizes the foregoing invention purpose is:
A kind of edible composition that increases bone density is characterized in that, described composition comprises following component and dosage:
(1) Shorthorned Epimedium P.E (in icariine) 25～600mg/kg;
(2) collagen 25～600mg/kg.
Preferred dose wherein:
(1) barrenwort (in icariine) 200mg/kg;
(2) collagen 135mg/kg.
The edible composition of described increase bone density is characterized in that, this collagen is an ossein.
The edible composition of described increase bone density is characterized in that, this collagen is a collagen.
The specific embodiment
Embodiment 1
Below increase bone density functional component and dosage by a screening zoopery further specify the present invention, wherein: the composition of this each component of edible composition is: component 1 Shorthorned Epimedium P.E (in icariine), component 2 kudzu root extracts, component 3 calcium carbonate, component 4 collagens, component 5 magnesium carbonate, component 6 vitamin Ks.
1 test objective
With calcium carbonate as positive control, carry out the zoopery experimental design with the weight method of completing the square, screening 6 kinds of compositions and 6 dosage per os is tried behind the thing to increase the influence of bone density function to extracing the ovary rat, and carry out each composition interphase interaction dynamic analysis of each index, in the hope of finding out optimum formula.Form the functional product prescription that increases the bone density function.
2 experiment materials and method
2.1 tried thing
Title: tried thing 1～No. 6, calcium carbonate.
The unit of providing: Only Co., Ltd., Shanghai Jiantong Univ..
Solvent: 0.5% sodium carboxymethylcellulose.
Compound method: precision takes by weighing that to be tried thing an amount of, is mixed with desired concn with 0.5% sodium carboxymethylcellulose, presses the capacity gastric infusion of 0.5ml/100g rat.
2.2 animal used as test
6 month female SD rats, available from Shanghai west pul-Bi Kai animal used as test Co., Ltd, the animal quality quality certification number: SCXK (Shanghai) 2003-0002.
2.3 main agents and instrument
2.3.1 feed formula:
With reference to AIN93 feed formula preparation semi-finished product feed, with the composition that derives from soybean in the suitable substitution of materials feed, to avoid of the interference of phytoestrogen such as isoflavones to result of the test.Feed formula sees the following form:
Table 1: feed formula
1. select low calcium casein for use
2. prepare according to AIN93M mixed mineral salt.Fill a prescription in following (g/kg mixture): potassium dihydrogen phosphate 250.0; Sodium chloride 74.0; Potassium sulfate 46.6; Potassium citrate (single crystals water) 28.0; Magnesia 24.0; Ferrum citricum 6.06; Zinc carbonate 1.65; Manganese carbonate 0.63; Copper carbonate 0.30; KI 0.01; Sodium selenate 0.01025; To amine molybdate 0.00795; Sodium metasilicate (9 crystallizations water) 1.45; Chromium potassium suplhate (12 crystallizations water) 0.275; Boric acid 0.0815; Sodium fluoride 0.0635; Nickelous carbonate 0.0318; Lithium chloride 0.0174; Ammonium vanadate 0.0066; With sucrose to 1kg.
3. according to the preparation of AIN93M mixed vitamin, fill a prescription following (g/kg mixture): nicotinic acid 3.0; Calcium pantothenate 1.6; Puridoxine hydrochloride 0.70; Thiamine hydrochloride 0.60; VitB
20.60; Folic acid 0.20; Biotin 0.020; VitB
122.50; VitE (500IU/g) 15.0; VitA (palmitate, 500000IU/g) 0.8; VitD
3(400000IU/g) 0.25; VitK0.075; Sucrose 974.655.
2.3.2 main agents
Yellow Jackets (lot number: F20021216, China Medicine (Group) Shanghai Chemical Reagent Co.); CMC-Na (lot number: F20050621, Chemical Reagent Co., Ltd., Sinopharm Group); Lanthanum chloride (lot number: F20041119, Chemical Reagent Co., Ltd., Sinopharm Group); Hydrochloric acid (lot number: 050930486, Nanjing Chemistry Reagent Co., Ltd.).Serum alkaline phosphatase (s-ALP), creatinine (Cr), hydroxyproline and serum paraoxonase (s-P) kit are Nanjing and build up Bioisystech Co., Ltd's product; The estradiol radioimmunological kit is Tianjin Jiuding Medical Biological Engineering Co., Ltd's product.
2.3.3 key instrument
The Hologic QDR-4000 type dual-energy x-ray bone density meter (place of production: the U.S.); The AA-670 atomic absorption spectrophotometer, day island proper Tianjin company; The gamma-rays analyzer, University of Science and Technology, Anhui Creative Company; SPJX type high-temperature electric resistance furnace (muffle furnace), PVG Rong Feng scientific instrument Co., Ltd; BS110S type electronic balance, German sartorius; 722 type visible light light-splitting photometers, Shanghai essence science and technology Instr Ltd.; HH-2 digital display thermostat water bath, state China Electrical Appliances Co., Ltd; Slide measure; 2000N spring pressure testing machine; Resistance strain gauge force transducer; Displacement transducer; The programmable data recorder; The electric heating constant temperature dual-purpose case; Centrifugal precipitation mechanism.
2.4 experimental technique
Requirement according to " health food check and evaluation " version in 2003 is carried out
2.4.1 oophorectomy and postoperative examination:
With rat with 30mg/kg yellow Jackets 0.5ml/100g intraperitoneal injection of anesthesia after, under the most last rib of rat back, midaxillary line and apart from the about 2cm infall cropping of the backbone outside is in aseptic condition excision bilateral ovaries down in ventrimeson for fixing back, abdomen position.After hindlimb muscle is injected 20,000 U penicillin.For guaranteeing perform the operation successfully, behind the rat excision ovary 5 days, carry out vaginal smear examination and (draw a small amount of physiological saline with dropper, insert vagina 1～2cm gently, flushing is the back sucking-off for several times, is applied on the slide, and mirror is observed down), once a day, continuous 7 days, to check whether fully excision of rat ovary; Be emotionally reaction (seeing translucent, flat in a large number epidermal cell under the mirror) as smear, show the animal ovary excision not exclusively, promptly discarding need not.Sham-operation group bilateral excises a fritter fat as negative control.
2.4.2 animal grouping and dosage
Get the survival healthy rat after 7 days, be divided into 8 groups at random.That is: sham-operation group, pathological model group, positive controls, 1 group of compatibility, 2 groups of compatibilities, 3 groups of compatibilities, 4 groups of compatibilities, 5 groups of compatibilities, 6 groups of compatibilities.1～6 group of compatibility is according to the design that experimentizes of weight method of experimental design, and the weight design table sees Table 2, and concrete dosage sees Table 3.
Table 3: the divide into groups dosage of each component of animal used as test:
Postoperative 5 days per os respectively gives following medicine: sham-operation group (Sham): 0.5%CMC-Na solution 5ml/kg/d; Pathological model group (Model): 0.5%CMC-Na solution 5ml/kg/d; Positive controls: calcium carbonate group 501mg/kg/d; Group 1:1 medicine 774.15mg/kg/d; Group 2:2 medicine 817.57mg/kg/d; Group 3:3 medicine 1311.79mg/kg/d; Group 4:4 medicine 568.94mg/kg/d; Group 5:5 medicine 1076.36mg/kg/d; Group 6:6 medicine 1021.79mg/kg/d, administration every day 1 time was tried thing 3 months continuously.Each is organized rat and all drinks deionized water, edible self-control feed.
2.4.3 experimental index and sampling
In the experimentation, the weighing rat body weight once weekly.Finish preceding 2 weeks in experiment, the eye socket veniplex is got blood, and separation of serum is measured serum estradiol, alkaline phosphatase and thermally-stabilised alkaline phosphatase (56 ℃ of deactivation 15min of water-bath, the same alkaline phosphatase of assay method) content.To deduct thermally-stabilised content of alkaline phosphatase be thermal instability alkaline phosphatase (HIS-ALP) content to TALP content in the serum.When experiment finished, the execution animal peeled off the left side femur rapidly and is used to measure bone density with the gauze parcel that physiological saline soaks.The right side femur is dry in 110 ℃ of baking ovens, and weighing is key heavy.Dry femur charing is placed in the muffle furnace 650 ℃ of ashing 8 hours, and the weighing bone ash is heavy.Bone ash is dissolved in the 6mol/L HCl solution, measures bone calcium, phosphorus content.
2.5 data are handled
2.5.1 positive controls, sham-operation group and pathological model group test data are carried out homogeneity test of variance earlier, variance is neat, then organizes comparing in twos of a mean; Heterogeneity of variance then carries out the conversion of suitable variable, adds up with the data after changing after waiting to satisfy the neat requirement of variance.
2.5.2 1～6 group of rat data of compatibility use DAS software to carry out the drug interaction dynamic analysis.
3 result of the tests
3.1 respectively tried the influence of thing to rat body weight
By table 4 as seen, the body weight of removal ovary rat obviously increases, and group 1,4 average weights significantly are lower than model group (p＜0.05) during to the 12nd week.
Table 4: the variation (n=12, g, the x ± SD) that respectively organize rat body weight before and after the experiment
Compare with the Sham group
*P＜O.05; Organize #p＜0.05 of comparing with Model,
3.2, the variation between sham-operation group, model group and each index of positive controls
3.2.1 the variation of serological index
Compare with the sham-operation group, model group rat bone alkaline phosphatase significantly raises (p＜0.05), and the serum estradiol level significantly reduces (p＜0.01).Show the modeling success.
Compare the equal not statistically significant of difference of the total ALP of positive drug group, serum estradiol with model group.See Table 5.
Table 5: to the influence of removal ovary osteoporosis rat hematological indices (n=12, x ± SD)
#P＜0.05, book group (Sham) is compared with doing evil through another person
3.2.2 the variation of bone mineral content
Compare with the sham-operation group, the calcium in the model group femur, phosphorus content all obviously reduce (p＜0.05).Show the modeling success.
Compare with model group, calcium carbonate group bone calcium and bone phosphorus content raise to some extent, but all do not have significant difference (p＞0.05).See Table 6.
Table 6: to the influence of heavy coefficient of removal ovary osteoporosis rat femur ash and bone mineral content (n=12, x ± SD)
Compare with sham-operation (Sham) group in #p＜0.05,
*Compare with the Model group in p＜0.05
3.2.3 the variation of bone mineral density
The DEXA Measurement results shows, compares with the sham-operation group, and the model group bone density significantly reduces (p＜0.05), shows the modeling success; Compare with model group, calcium carbonate group bone density slightly raises, but not statistically significant sees Table 7.
Table 7: to the influence of removal ovary osteoporosis rat femur bone mineral density (n=12, x ± SD)
Compare with sham-operation (Sham) group in #p＜0.05,
Adopt for 1～No. 6 DAS software to analyze 3.3 be subjected to reagent
3.3.1 analysis result to bone density
Table 8:DAS software is to the analysis result of bone density
Drug interaction dynamic analysis result (weight method of completing the square) bone density 2SD
DAS 2.0.1 analyzes date: 2006-10-25
Each organizes different component dosage and coupling drug effect (E)
The relation of markization dosage (di) and coupling drug effect (E)
Each component significance level and RD
Each component is the significance level ordering in prescription: component 1＞component 4＞component 6＞component 3＞component 5＞component 2
The relation of main medicine d1 and mutual (didj) and coupling drug effect (E)
Mutual (didj) of main medicine d1 deposits dosage with pushing away
Mutual significance level ordering: d1＞d1d4＞d1d6＞d1d3＞d1d5＞d1d2
Annotate: d1 is for reference usefulness, and RD is the dosage with the d1 interaction component in the table
3.3.2 to bone ensaying result
3.3.2.1 DAS software is to bone calcium/dry weight analysis result
Table 9:DAS software is to bone calcium/dry weight analysis result
Drug interaction dynamic analysis result (weight method of completing the square) bone calcium/dry weight 2SD
DAS 2.0.1 analyzes date: 2006-10-25
Each organizes different component dosage and coupling drug effect (E)
The relation of markization dosage (di) and coupling drug effect (E)
Each component significance level and RD
Each component is the significance level ordering in prescription: component 1＞component 4＞component 6＞component 3＞component 5＞component 2
The relation of main medicine d1 and mutual (didj) and coupling drug effect (E)
Mutual (didj) of main medicine d1 deposits dosage with pushing away
Mutual significance level ordering: d1＞d1d4＞d1d6＞d1d3＞d1d5＞d1d2
Annotate: d1 is for reference usefulness, and RD is the dosage with the d1 interaction component in the table
3.3.2.2 DAS software is to bone phosphorus/dry weight analysis result
Table 10:DAS software is to bone phosphorus/dry weight analysis result
Drug interaction dynamic analysis result (weight method of completing the square) bone phosphorus/dry weight 2SD
DAS 2.0.1 analyzes date: 2006-10-25
Each organizes different component dosage and coupling drug effect (E)
The relation of markization dosage (di) and coupling drug effect (E)
Each component significance level and RD
Each component is the significance level ordering in prescription: component 1＞component 4＞component 6＞component 3＞component 5＞component 2
The relation of main medicine d1 and mutual (didj) and coupling drug effect (E)
Mutual (didj) of main medicine d1 deposits dosage with pushing away
Mutual significance level ordering: d1＞d1d4＞d1d6＞d1d3＞d1d5＞d1d2
Annotate: d1 is for reference usefulness, and RD is the dosage with the d1 interaction component in the table
3.3.3 DAS software is to bone alkaline phosphatase activity analysis result
Table 11:DAS software is to bone alkaline phosphatase activity analysis result
Drug interaction dynamic analysis result (weight method of completing the square) bone ALP 2SD
DAS 2.0.1 analyzes date: 2006-10-25
Each organizes different component dosage and coupling drug effect (E)
The relation of markization dosage (di) and coupling drug effect (E)
Each component significance level and RD
Each component is the significance level ordering in prescription: component 1＞component 4＞component 3＞component 6＞component 5＞component 2
The relation of main medicine d1 and mutual (didj) and coupling drug effect (E)
Mutual (didj) of main medicine d1 deposits dosage with pushing away
Mutual significance level ordering: d1d3＞d1＞d1d6＞d1d4＞d1d5＞d1d2
Annotate: d1 is for reference usefulness, and RD is the dosage with the d1 interaction component in the table
2.3.3.2 DAS software is to the serum estradiol analysis result
Table 12:DAS software is to the serum estradiol analysis result
Drug interaction dynamic analysis result (weight method of completing the square) serum estradiol 2SD
DAS 2.0.1 analyzes date: 2006-10-25
Each organizes different component dosage and coupling drug effect (E)
The relation of markization dosage (di) and coupling drug effect (E)
Each component significance level and RD
Each component is the significance level ordering in prescription: component 2＞component 3＞component 6＞component 5＞component 4＞component 1
The relation of main medicine d2 and mutual (didj) and coupling drug effect (E)
Mutual (didj) of main medicine d2 deposits dosage with pushing away
Mutual significance level ordering: d2d3＞d2d6＞d2d5＞d2d4＞d2＞d2d1
Annotate: d2 is for reference usefulness, and RD is the dosage with the d2 interaction component in the table
[conclusion]
Can see that from The above results model group rat bone alkaline phosphatase activities significantly raises, serum estradiol content, bone calcium, bone phosphorus, bone density content significantly reduce, and illustrate that the removal ovary rat model successfully sets up.
Adopt the weight experimental design, with the dose-effect relationship of 6 components of removal ovary rat model screening and 6 dosage increase bone density functions.Result after experimental data is handled with DAS software is as follows: leading indicator: bone density, bone calcium/dry weight, and the significance level ordering of 6 components is: 1＞4＞6＞3＞5＞2; Other indexs: bone phosphorus/dry weight, the significance level ordering of 6 components is: 1＞4＞6＞3＞5＞2; The activity of bone alkaline phosphatase, the significance level ordering of 6 components is: 1＞4＞3＞6＞5＞2; Serum estradiol content, the significance level ordering of 6 components is: 2＞3＞6＞5＞4＞1.From the interaction relationship of 6 components to each index, leading indicator: bone density, bone calcium/dry weight, component 1 and component 2 are mutual antagonism relation, component 1 and component 3 are the relation of antagonism mutually, component 1 and component 4 are mutual conspiracy relation, component 1 and component 5 are mutual antagonism relation, and component 1 and component 6 are mutual antagonism relation; Other indexs: bone phosphorus/dry weight, component 1 and component 2 are mutual antagonism relation, and component 1 and component 3 are mutual antagonism relation, and component 1 and component 4 are mutual conspiracy relation, and component 1 and component 5 are mutual antagonism relation, and component 1 and component 6 are mutual antagonism relation; The activity of bone alkaline phosphatase, the interaction between each component is: component 1 and component 2 are the addition relation, and component 1 and component 3 are mutual conspiracy relation, and component 1 and component 4, component 5, component 6 are the addition relation; Serum estradiol, interaction between each component is: component 2 and component 1 are mutual antagonism relation, and component 2 and component 3 are mutual conspiracy relation, and component 2 and component 4 are mutual antagonism relation, component 2 and component 5, component 6 are mutual conspiracy relation, and component 1 and component 6 are mutual conspiracy relation.According to the importance of each index in increasing the bone density evaluation, and the correlation between each component as can be seen, and 4 pairs of removal ovary rats of component 1 and component increase the bone density effect and have synergy.Its RD is: component 1 is: 200mg/kg, component 4 is: 134.74mg/kg.
In sum, show to have the active principle that increases the Osteoporosis Rats bone density to be by setting up the experiment that removal ovary osteoporosis rat model screens 6 components and 6 dosage: component 1 and component 4, and the two has synergy.Proposed recommendations dosage is: component 1 is: 200mg/kg, component 4 is: 135mg/kg.
Embodiment 2
Screen the dosage range that increases the bone density functional component by further zoopery and further specify the present invention, wherein: the composition of this each component of edible composition is: component 1 is Shorthorned Epimedium P.E (in icariine), dosage is 25mg/kg, 300mg/kg, 600mg/kg; Component 2 is a collagen, and dosage is 25mg/kg, 300mg/kg, 600mg/kg.
1 test objective
On the basis of experiment I The selection result, further screen fraction 1 (Shorthorned Epimedium P.E) and component 4 (collagen) are to increasing the dosage effect of bone density, in the hope of finding out 4 pairs of effective dosage ranges that increase the bone density function of component 1 and component.
2 experiment materials and method
2.1 tried thing
Title: tried thing 1～No. 3, calcium carbonate.
The unit of providing: Only Co., Ltd., Shanghai Jiantong Univ..
Solvent: 0.5% sodium carboxymethylcellulose.
Compound method: precision takes by weighing that to be tried thing an amount of, is mixed with desired concn with 0.5% sodium carboxymethylcellulose, presses the capacity gastric infusion of 0.5ml/100g rat.
2.2 animal used as test
6 month female SD rats, available from Shanghai west pul-Bi Kai animal used as test Co., Ltd, the animal quality quality certification number: SCXK (Shanghai) 2003-0002.
2.3 main agents and instrument
2.3.1 feed formula:
With reference to AIN93 feed formula preparation semi-finished product feed, with the composition that derives from soybean in the suitable substitution of materials feed, to avoid of the interference of phytoestrogen such as isoflavones to result of the test.Feed formula sees the following form:
Table 1: feed formula
1. select low calcium casein for use
2. prepare according to AIN93M mixed mineral salt.Fill a prescription in following (g/kg mixture): potassium dihydrogen phosphate 250.0; Sodium chloride 74.0; Potassium sulfate 46.6; Potassium citrate (single crystals water) 28.0; Magnesia 24.0; Ferrum citricum 6.06; Zinc carbonate 1.65; Manganese carbonate 0.63; Copper carbonate 0.30; KI 0.01; Sodium selenate 0.01025; To amine molybdate 0.00795; Sodium metasilicate (9 crystallizations water) 1.45; Chromium potassium suplhate (12 crystallizations water) 0.275; Boric acid 0.0815; Sodium fluoride 0.0635; Nickelous carbonate 0.0318; Lithium chloride 0.0174; Ammonium vanadate 0.0066; With sucrose to 1kg.
3. according to the preparation of AIN93M mixed vitamin, fill a prescription following (g/kg mixture): nicotinic acid 3.0; Calcium pantothenate 1.6; Puridoxine hydrochloride 0.70; Thiamine hydrochloride 0.60; VitB
20.60; Folic acid 0.20; Biotin 0.020; VitB
122.50; VitE (500IU/g) 15.0; VitA (palmitate, 500000IU/g) 0.8; VitD
3(400000IU/g) 0.25; VitK0.075; Sucrose 974.655.
2.3.2 main agents
Yellow Jackets (lot number: F20021216, China Medicine (Group) Shanghai Chemical Reagent Co.); CMC-Na (lot number: F20050621, Chemical Reagent Co., Ltd., Sinopharm Group); Lanthanum chloride (lot number: F20041119, Chemical Reagent Co., Ltd., Sinopharm Group); Hydrochloric acid (lot number: 050930486, Nanjing Chemistry Reagent Co., Ltd.).Serum alkaline phosphatase (s-ALP), creatinine (Cr), hydroxyproline and serum paraoxonase (s-P) kit are Nanjing and build up Bioisystech Co., Ltd's product; The estradiol radioimmunological kit is Tianjin Jiuding Medical Biological Engineering Co., Ltd's product.
2.3.3 key instrument
The Hologic QDR-4000 type dual-energy x-ray bone density meter (place of production: the U.S.); The AA-670 atomic absorption spectrophotometer, day island proper Tianjin company; The gamma-rays analyzer, University of Science and Technology, Anhui Creative Company; SPJX type high-temperature electric resistance furnace (muffle furnace), PVG Rong Feng scientific instrument Co., Ltd; BS110S type electronic balance, German sartorius; 722 type visible light light-splitting photometers, Shanghai essence science and technology Instr Ltd.; HH-2 digital display thermostat water bath, state China Electrical Appliances Co., Ltd; Slide measure; 2000N spring pressure testing machine; Resistance strain gauge force transducer; Displacement transducer; The programmable data recorder; The electric heating constant temperature dual-purpose case; Centrifugal precipitation mechanism.
2.4 experimental technique
Requirement according to " health food check and evaluation " version in 2003 is carried out
2.4.1 oophorectomy and postoperative examination:
With rat with 30mg/kg yellow Jackets 0.5ml/100g intraperitoneal injection of anesthesia after, under the most last rib of rat back, midaxillary line and apart from the about 2cm infall cropping of the backbone outside is in aseptic condition excision bilateral ovaries down in ventrimeson for fixing back, abdomen position.After hindlimb muscle is injected 20,000 U penicillin.For guaranteeing perform the operation successfully, behind the rat excision ovary 5 days, carry out vaginal smear examination and (draw a small amount of physiological saline with dropper, insert vagina 1～2cm gently, flushing is the back sucking-off for several times, is applied on the slide, and mirror is observed down), once a day, continuous 7 days, to check whether fully excision of rat ovary; Be emotionally reaction (seeing translucent, flat in a large number epidermal cell under the mirror) as smear, show the animal ovary excision not exclusively, promptly discarding need not.Sham-operation group bilateral excises a fritter fat as negative control.
2.4.2 animal grouping and dosage
Get the survival healthy rat after 7 days, be divided into 6 groups at random.That is: sham-operation group, pathological model group, positive controls, 1 group of dosage, 2 groups of dosage, 3 groups of dosage.That is:
1, sham-operation group:
2, pathological model group:
3, positive controls:
4, dosage is 1 group: Shorthorned Epimedium P.E (in icariine) 25mg+ collagen 25mg
5, dosage is 2 groups: Shorthorned Epimedium P.E (in icariine) 300mg+ collagen 300mg
6, dosage is 3 groups: Shorthorned Epimedium P.E (in icariine) 600mg+ collagen 600mg
Postoperative 5 days per os respectively gives following medicine: sham-operation group (Sham): 0.5%CMC-Na solution 5ml/kg/d; Pathological model group (Model): 0.5%CMC-Na solution 5ml/kg/d; Positive controls: calcium carbonate group 501mg/kg/d; 1 group of dosage is tried thing 50mg/kg/d; 2 groups of dosage are tried thing 600mg/kg/d; 3 groups of dosage are tried thing 1200mg/kg/d; Administration every day 1 time was tried thing 3 months continuously.Each is organized rat and all drinks deionized water, edible self-control feed.
2.4.3 experimental index and sampling
In the experimentation, the weighing rat body weight once weekly.Finish preceding 2 weeks in experiment, the eye socket veniplex is got blood, and separation of serum is measured serum estradiol, alkaline phosphatase and thermally-stabilised alkaline phosphatase (56 ℃ of deactivation 15min of water-bath, the same alkaline phosphatase of assay method) content.To deduct thermally-stabilised content of alkaline phosphatase be thermal instability alkaline phosphatase (HIS-ALP) content to TALP content in the serum.When experiment finished, the execution animal peeled off the left side femur rapidly and is used to measure bone density with the gauze parcel that physiological saline soaks.The right side femur is dry in 110 ℃ of baking ovens, and weighing is key heavy.Dry femur charing is placed in the muffle furnace 650 ℃ of ashing 8 hours, and the weighing bone ash is heavy.Bone ash is dissolved in the 6mol/L HCl solution, measures bone calcium, phosphorus content.
2.5 data are handled
Carry out homogeneity test of variance earlier 2.5.1 respectively organize the rat test data, variance is neat, then organizes the comparison of a mean; Heterogeneity of variance then carries out the conversion of suitable variable, adds up with the data after changing after waiting to satisfy the neat requirement of variance.
3 result of the tests
3.1 respectively tried the influence of thing to rat body weight
By table 4 as seen, the body weight of removal ovary rat obviously increases, and group 1,4 average weights significantly are lower than model group (p＜0.05) during to the 12nd week.
Table 2: the variation (n=12, g, the x ± SD) that respectively organize rat body weight before and after the experiment
Compare with the Sham group
*P＜0.05; Organize #p＜0.05 of comparing with Model,
3.2, the variation between each index of each experimental group
3.2.1 the variation of serological index
Compare with the sham-operation group, model group rat bone alkaline phosphatase significantly raises (p＜0.05), and the serum estradiol level significantly reduces (p＜0.01).Show the modeling success.
Compare the equal not statistically significant of difference of positive drug group bone ALP, serum estradiol with model group.Compare with model group, 1 group of dosage, 2 groups of dosage, 3 groups of rat bone alkaline phosphatases of dosage significantly reduce (p＜0.05), serum estradiol level significantly raise (p＜0.01).Show that 1 group of dosage, 2 groups of dosage, dosage all have the function that increases bone density for 3 groups.See Table 3.
Table 3: to the influence of removal ovary osteoporosis rat hematological indices (n=12, x ± SD)
#P＜0.05, book group (Sham) is compared with doing evil through another person;
*Compare with model group in P＜0.05.
3.2.2 bone mineral content and changes of bone mineral density
Compare with the sham-operation group, the calcium in the model group femur, phosphorus content all obviously reduce; The DEXA Measurement results shows that the model group bone density significantly reduces (p＜0.05), shows the modeling success; (p＜0.05).
Compare with model group, calcium carbonate group bone calcium, bone phosphorus content and bone density raise to some extent, but all do not have significant difference (p＞0.05).
Compare 1 group of dosage, 2 groups of dosage, 3 groups of rat bone calcium of dosage, bone phosphorus content and bone density significantly raise (p＜0.01) with model group.Show that 1 group of dosage, 2 groups of dosage, dosage all have the function that increases bone density for 3 groups.See Table 4.
Table 4: to the influence of heavy coefficient of removal ovary osteoporosis rat femur ash and bone mineral content (n=12, x ± SD)
Compare with sham-operation (Sham) group in #p＜0.05,
*Compare with the Model group in p＜0.05
[conclusion]
Can see that from The above results model group rat bone alkaline phosphatase activities significantly raises, serum estradiol content, bone calcium, bone phosphorus, bone density content significantly reduce, and illustrate that the removal ovary rat model successfully sets up.
Compare with model group, 1 group of dosage, 2 groups of dosage, 3 groups of rat bone alkaline phosphatase activitieses of dosage significantly reduce, the serum estradiol level significantly raises, bone calcium, bone phosphorus, bone density content significantly increase, and illustrates that 1 group of dosage, 2 groups of dosage, dosage all have the effects that increase bone density for 3 groups.
In sum, show by setting up the experiment that removal ovary osteoporosis rat model screens Shorthorned Epimedium P.E and collagen dosage range, having the dosage range that increases Osteoporosis Rats bone density active principle is: Shorthorned Epimedium P.E (in icariine) is 25～600mg/kg, collagen is 25～600mg/kg, wherein: preferred dose: Shorthorned Epimedium P.E (in icariine) 200mg/kg; (2) collagen is 135mg/kg.
Claims (4)
1. an edible composition that increases bone density is characterized in that, described composition comprises following component and dosage:
(1) Shorthorned Epimedium P.E (in icariine) 25～600mg/kg;
(2) collagen 25～600mg/kg.
2. the edible composition of increase bone density according to claim 1 is characterized in that, the preferred dose of described composition:
(1) barrenwort (in icariine) 200mg/kg;
(2) collagen 135mg/kg.
3. the edible composition of increase bone density according to claim 1 and 2 is characterized in that, this collagen is an ossein.
4. the edible composition of increase bone density according to claim 1 and 2 is characterized in that, this collagen is a collagen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101483832A CN101209111A (en) | 2006-12-30 | 2006-12-30 | Edible composition capable of increasing bone density |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101483832A CN101209111A (en) | 2006-12-30 | 2006-12-30 | Edible composition capable of increasing bone density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101209111A true CN101209111A (en) | 2008-07-02 |
Family
ID=39609499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101483832A Pending CN101209111A (en) | 2006-12-30 | 2006-12-30 | Edible composition capable of increasing bone density |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101209111A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816431A (en) * | 2010-04-30 | 2010-09-01 | 浙江省医学科学院 | Precious peptide bone-strengthening capsules or tablets with function of improving osteoporosis and increasing bone mineral density and preparation method thereof |
-
2006
- 2006-12-30 CN CNA2006101483832A patent/CN101209111A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816431A (en) * | 2010-04-30 | 2010-09-01 | 浙江省医学科学院 | Precious peptide bone-strengthening capsules or tablets with function of improving osteoporosis and increasing bone mineral density and preparation method thereof |
| CN101816431B (en) * | 2010-04-30 | 2012-11-28 | 浙江省医学科学院 | Precious peptide bone-strengthening capsules or tablets with function of improving osteoporosis and increasing bone mineral density and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095751B (en) | Medicinal composition having functions of removing chloasma and improving nutritional anemia and method for preparing the same | |
| CN102090630A (en) | Health-care product for enhancing antioxidation of human bodies and preparation method thereof | |
| CN102258549B (en) | New application of cynomorium songaricum extract in preparing medicines for treating female climacteric syndrome | |
| CN101209111A (en) | Edible composition capable of increasing bone density | |
| CN102266415B (en) | Application of compound traditional Chinese medicine in prevention and treatment of osteoporosis disease | |
| CN104383447B (en) | A kind of Traditional Chinese medicine composition and preparation method and application | |
| CN103169864A (en) | Fluid-increasing decoction formula granules and preparation method, application and detection method thereof | |
| CN106236799A (en) | The application in preparation treatment perimenopausal syndrome medicine of the Fructus Cnidii total flavones | |
| CN102895283A (en) | Xi Huang dropping pill molding process | |
| CN1814048B (en) | Chinese medicine liquid capsule of Folium callicarpae Nudiflorae, preparing method and quality control method | |
| CN101380359A (en) | Jiangu capsules and preparation method thereof | |
| CN101793656A (en) | Method for testing decocting rate of traditional Chinese medicine decoction | |
| CN103520350B (en) | Traditional Chinese medicine for treating functional uterine bleeding | |
| CN107874060A (en) | A kind of hypoglycemic health food and preparation method thereof | |
| CN101019897A (en) | Antitumor medicine composition and its prepn | |
| CN104000896B (en) | A kind of Malus toringoides (Rehd.) Hughes extract and preparation method thereof and its purposes | |
| CN107258986A (en) | Wormwood brown sugar warms up tea and preparation method thereof | |
| CN102652774A (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN106562415A (en) | Health food and preparation method thereof | |
| CN1895504A (en) | Chinese medicine for treating osteoporosis and its preparation | |
| Goel et al. | Polycystic ovarian syndrome | |
| CN102764341B (en) | Traditional Chinese medicinal composition preparation for clearing heat, detoxifying, cooling blood and reducing swelling and preparation method thereof | |
| CN104173734A (en) | Pharmaceutical composition for treating impaired glucose regulation and preparation method thereof | |
| CN104256576A (en) | Functional food capable of regulating blood pressure | |
| CN107875184A (en) | A kind of Radix Berberidis extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080702 |